Key Highlights

  • During Friday's session on November 6, 2026, MetaVia was trading up 23.85% at USD 1.35, measured against a prior close of USD 1.09 on a published market data page.
  • A November 5 headline described interim Phase 1 Part 3B DA-1726 results showing a statistically significant 68% cut in liver fat, but no complete write-up was available.
  • Across the trailing 52 weeks the shares have ranged from USD 0.966 to USD 13.42, leaving the latest price about 90% under the peak, a calculated gap.
  • Sarah Browne, the chief medical officer, presented DA-1726 Phase 1 findings in Denver at the Precision Liver Symposium on November 4, 2026, an event disclosed on October 28.

The Headline Liver Fat Figure Behind the Jump

MetaVia (NASDAQ:MTVA) gained after a November 5, 2026 headline reported favorable interim Phase 1 Part 3B results for DA-1726, including a statistically significant 68% decline in liver fat as measured by MRI-PDFF. Because the complete release was not accessible, cohort sizes, dosing and control groups are still unknown. DA-1726 is an oxyntomodulin analogue engineered to stimulate GLP-1 and glucagon receptors, intended as a once-weekly injection for obesity and metabolic liver disease. An October 28 notice had already flagged that Sarah Browne, the chief medical officer, would present the material on November 4. The chronology points to the rally following the data, though no company statement confirms that causation.

Previous Weight-Loss Readouts Shape Expectations

Headlines earlier in 2026 pointed to a 48 mg group that achieved mean body-weight loss of up to 9.1% at Day 54 with no plateau, and management has called the 32 mg level best-in-class in potential. Such statements come from small early studies and were not compared head-to-head with approved GLP-1 medicines. A liver-fat improvement seen in a modest cohort offers no guarantee for later-stage success. Dose titration in the Phase 1 Part 3 obesity trial finished in July. Investors commonly weigh liver fat, weight change, tolerability and preservation of lean mass together, yet only a subset of those measures appears in the material available here.

Capitalization, Reverse Split and Cash Unknowns

At roughly USD 1.36 a share with 6.59 million shares outstanding, the company's valuation was listed near USD 8.96 million, a very small figure for a clinical-stage developer. Investors signed off on a reverse split at the 2026 annual gathering, and a public notice cited a 1-for-11 ratio, though the effective date has not been verified. Management's risk disclosures question whether current cash is adequate, and no balance-sheet figure was located. A share base this compact makes a fresh capital raise a plausible follow-on to any rally. Quoted moves may evaporate and spreads may be wide, and the data page showed roughly 768 thousand shares changing hands, thin trading behind a 24.77% swing so far this session.

Where Things Stand

The jump appears connected to the November 5 interim DA-1726 readout, but no company statement draws that link directly. The 68% liver fat decline exists only in a headline, which leaves the full dataset, comparators and funding picture unverified. A value near USD 9 million means a handful of trades can shift the price. The checkpoints ahead are the complete data release and poster, plus the reverse-split details and the third-quarter report.